AAP
AZN icon

Ardsley Advisory Partners’s AstraZeneca AZN Stock Holding History

Ardsley Advisory Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-67,150
Closed -$4.18M – 142
2017
Q1 		$4.18M Buy
+67,150
New +$3.91M 0.65% 52

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ardsley Advisory Partners's AZN Position: Q4 2022 in Review

Ardsley Advisory Partners sold out of AstraZeneca (AZN) in Q4 2022, closing a stake of 50,000 shares — an estimated $5.48M sold.

Ardsley Advisory Partners first reported a position in AZN in Q4 2019 and held it in 9 quarters. The position peaked at $18.1M in Q3 2021. 1,062 funds tracked by Wall St. Rank hold AZN as of Q4 2022.

  • Ardsley Advisory Partners reported no remaining AstraZeneca position as of Q4 2022 after selling out during the quarter.
  • Ardsley Advisory Partners sold 50,000 AstraZeneca shares in Q4 2022, an estimated $5.48M.
  • Ardsley Advisory Partners first reported a position in AstraZeneca in Q4 2019 and held it in 9 quarters.
  • Ardsley Advisory Partners's AstraZeneca position peaked at $18.1M in Q3 2021.
  • 1,062 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2022.

Based on Ardsley Advisory Partners's 13F filing for Q4 2022, filed 14 Feb 2023.